The rate of invasive fungal infections has surged in recent decades, augmenting the demand for antifungal agents. The North American region is the biggest shareholder of the global antifungal agents market in terms of revenue generation. It is estimated to grow at a 2.80% CAGR by the end of the forecast period of 2018-2026. The countries analyzed in this report include the United States and Canada.
NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026
North America Antifungal Agents Market by Drug Types (Echinocandins, Azoles, Polyenes, Allylamines & Others) by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) by Applications (Topical Antifungal Drugs, Oral Drugs) by Geography
The rate of invasive fungal infections has surged in recent decades, augmenting the demand for antifungal agents. The North American region is the biggest shareholder of the global antifungal agents market in terms of revenue generation. It is estimated to grow at a 2.80% CAGR by the end of the forecast period of 2018-2026.
The countries analyzed in this report include the United States and Canada. Development of novel antifungal biopharmaceuticals, rising incidence of fungal infections, huge investments made in drug productions and government initiatives related to fungal infections and their treatment are supporting the growth of the antifungal market in the North America region. The market growth of antifungal drugs in the US is majorly being propelled by the high funding in the healthcare sector. The county is also expected to exhibit the highest CAGR in this market by the end of the forecast period. In the United States, histoplasmosis is one of the most common opportunistic infections among people with HIV/AIDS.
The dominant market giants for the antifungal drugs market in North America are GlaxoSmithKline, Arbor Pharmaceuticals Inc., Kramer Laboratories, Astellas Pharma Inc., Teva Pharmaceuticals, Abbott Laboratories, Merck Co, Vertex Pharmaceuticals, Gilead, Bayer Healthcare, Novartis, Pfizer, Johnson & Johnson, Baxter, and Sanofi- Aventis.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
- ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET
- MARKET DETERMINANTS
- MARKET DRIVERS
- POOR HYGIENE HABITS
- DEVELOPMENT OF DRUG RESISTANCE
- MARKET RESTRAINTS
- ALTERNATE TREATMENT OPTIONS
- REGULATORY ATMOSPHERE
- MARKET OPPORTUNITIES
- EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
- HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
- INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
- MARKET CHALLENGES
- GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
- SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
- RESISTANCE TO DRUGS
- RAPIDLY CHANGING TECHNOLOGY
- MARKET DRIVERS
- MARKET SEGMENTATION
- MARKET BY DRUG TYPES 2018-2026
- SYSTEMIC AZOLES
- TOPICAL AZOLES
- SYSTEMIC POLYENES
- TOPICAL POLYENES
- SYSTEMIC ECHINOCANDINS
- SYSTEMIC ANTIMETABOLICS
- OTHER SYSTEMIC
- OTHER TOPICAL
- OTHER DRUGS TYPES
- MARKET BY THERAPEUTIC INDICATIONS 2018-2026
- ASPERGILLOSIS MARKET
- DERMATOPHYTOSIS MARKET
- CANDIDIASIS MARKET
- OTHER THERAPEUTIC INDICATION MARKET
- MARKET BY APPLICATIONS 2018-2026
- TOPICAL ANTIFUNGAL AGENTS MARKET
- ORAL DRUGS MARKET
- MARKET BY TYPES 2018-2026
- PRESCRIPTION
- OVER THE COUNTER (OTC)
- MARKET BY DRUG TYPES 2018-2026
- KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
- BARGAINING POWER OF BUYER
- BARGAINING POWER OF SUPPLIER
- INTENSITY OF COMPETITIVE RIVALRY
- KEY BUYING CRITERIA
- VALUE CHAIN ANALYSIS
- MANUFACTURERS
- DISTRIBUTORS
- RETAILERS
- END-USERS
- REGULATORY FRAMEWORK
- REGULATION IN NORTH AMERICA
- OPPORTUNITY MATRIX
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES (U.S.)
- CANADA
- NORTH AMERICA
- COMPANY PROFILES
- COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- ABBOTT LABORATORIES.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ARBOR PHARMACEUTICALS, INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- BAXTER
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ASTELLAS PHARMA INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- BAYER HEALTHCARE
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- TEVA PHARMACEUTICALS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- GILEAD
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- GLAXOSMITHKLINE
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- JOHNSON & JOHNSON
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- KRAMER LABORATORIES
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- MERCK & CO.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- NOVARTIS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- PFIZER
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- SANOFI-AVENTIS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- VERTEX PHARMACEUTICALS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- COMPETITIVE LANDSCAPE
TABLE LIST
TABLE 1 NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
TABLE 2 SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION
TABLE 3 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)
TABLE 4 DRUG USES OF TRIAZOLES
TABLE 5 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC AZOLES 2018-2026 ($ MILLION)
TABLE 6 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)
TABLE 16 SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES
TABLE 17 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)
TABLE 18 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 19 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 22 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 23 ANTIFUNGAL POWDERS AND IT’S EFFECT
TABLE 24 ANTIFUNGAL OINTMENT AND IT’S EFFECT
TABLE 25 ANTIFUNGAL PASTES AND IT’S EFFECT
TABLE 26 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)
TABLE 27 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 28 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)
TABLE 29 NORTH AMERICA ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
TABLE 31 NORTH AMERICA ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)
TABLE 32 NORTH AMERICA ANTI-FUNGAL AGENT MARKET 2018-2026 ($ MILLION)
TABLE 33 NORTH AMERICA ANTI-FUNGAL MARKET BY COUNTRIES 2018-2026 ($ MILLION)
FIGURES LIST
FIGURE 1 NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
FIGURE 2 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 3 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 4 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 5 THE UNITED STATES ANTI-FUNGAL AGENTS MARKET 2018-2026 ($ MILLION)
FIGURE 6 CANADA ANTIFUNGAL AGENT MARKET 2018-2026 ($ MILLION)
FIGURE 7 ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS 2017 (%)
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES (U.S.)
- CANADA
- NORTH AMERICA
- MARKET SEGMENTATION
- MARKET BY DRUG TYPES 2018-2026
- SYSTEMIC AZOLES
- TOPICAL AZOLES
- SYSTEMIC POLYENES
- TOPICAL POLYENES
- SYSTEMIC ECHINOCANDINS
- SYSTEMIC ANTIMETABOLICS
- OTHER SYSTEMIC
- OTHER TOPICAL
- OTHER DRUGS TYPES
- MARKET BY THERAPEUTIC INDICATIONS 2018-2026
- ASPERGILLOSIS MARKET
- DERMATOPHYTOSIS MARKET
- CANDIDIASIS MARKET
- OTHER THERAPEUTIC INDICATION MARKET
- MARKET BY APPLICATIONS 2018-2026
- TOPICAL ANTIFUNGAL AGENTS MARKET
- ORAL DRUGS MARKET
- MARKET BY TYPES 2018-2026
- PRESCRIPTION
- OVER THE COUNTER (OTC)
- MARKET BY DRUG TYPES 2018-2026
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.